脐血造血干细胞移植研究进展

Advance in umbilical cord blood hematopoietic stem cell transplantation

脐血已逐渐成为异基因造血干细胞移植治疗中的一个重要的干细胞来源。尽管移植相关病死率稍高,但由于复发率较低、移植后患者的生存质量较高,接受脐血移植患者的存活率与其他类型的造血干细胞移植相当。脐血移植技术的不断改善也给患者带来了更好的移植疗效。双份脐血移植克服了脐血细胞数量不足的缺陷,扩大了脐血移植在高体重的儿童和成人患者中的应用。而减低剂量预处理方案的脐血移植则为一些老年患者提供了新的治疗选择。

Umbilical cord blood （CB） has now become a commonly used source of hematopoietic stem cells （HSCs） for al- logeneic transplantation. Many studies have shown a decreased relapse rate and an increased transplantation-related mortality rate with similar overall survival rates after allogeneic hematopoietic stem cell transplantation with CB as compared with oth- er donor sources. Substantial advances have been made resulting in better outcomes for our patients. The transplantation of double CB units has overcome the dose limitation and thus has markedly extended the use of CB to larger children and a- dults. Similarly, the use of reduced intensity conditioning in the CB transplantation setting has allowed the treatment of older patients who would be unable to tolerate the myeloablative regimens used in the original CB transplantation protocols.